This life science investment firm reported a slight decline in NAV and portfolio value, but highlighted clinical progress in key holdings and improving biotech market conditions. Management is focusing on maximizing value from mature assets.
The biopharmaceutical company reported Q3 2025 results, with solid product revenue but signs of near-term challenges requiring leadership changes to support growth and expansion.
The life sciences investor announces plans to return £250 million to shareholders and shift its focus to realizing value from mature portfolio companies.
The investment company reports changes in major shareholdings.
The biotechnology company reports positive interim results from Phase 2 trials of its gene therapy for a rare blinding condition.
The biopharmaceutical company reported strong Q2 2025 financial results, including $20.9 million in AUCATZYL net product revenue. The firm also received regulatory approvals for its lead therapy in the UK and EU, and is advancing its pipeline with planned trials in lupus nephritis and multiple sclerosis.
The life sciences investor navigates challenging conditions, delivering key milestones across its portfolio while maintaining a strong capital position.
The company has announced a change to its board of directors, with Virginia Holmes retiring and Kemal Malik taking on the role of Senior Independent Director.
The life science investor has published its annual report and notice of AGM for 2025.
This investment company faced a challenging year with a 9.5% decline in NAV per share and a 17% negative return on its life science portfolio, reflecting broader biotech sector headwinds and volatile market conditions.